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Mi Kwon,1,2 Carolina Martınez-Laperche,1,2 Marıa Infante,2 Fernando Carretero,2
Pascual Balsalobre,1,2 David Serrano,1,2 Jorge Gayoso,1,2 Ana Perez-Corral,2 Javier Anguita,1,2
Jose Luis Dıez-Martın,1,2 Ismael Bu~no1,2Relapse remains the main cause of treatment failure in patients with acute myelogeous leukemia (AML) after
allogeneic hemopoietic stem cell transplantation (SCT). TheWilms’ tumor 1 gene (WT1) is reportedly over-
expressed in .90% of patients with AML and thus can be useful for minimal residual disease (MRD) moni-
toring. The aim of this study was to evaluate the usefulness ofWT1 expression as a relapse predictor marker
in patients with AML after SCTand compare it with flow cytometry (FC) and chimerism studies. WT1 ex-
pression was assessed retrospectively using quantitative RT-PCR in bone marrow and peripheral blood from
21 patients. Patients were classified according to WT1 dynamics posttransplantation. Eleven of the 21 pa-
tients had low and stable WT1 levels. All of these 11 patients showed complete chimerism and negative
MRD by FC and remained in complete remission with a median follow-up of 27 months (range, 18-98
months). In contrast, 10 of 21 patients showed WT1 overexpression after SCT, and 9 of these 10 patients
relapsed. The incidence of relapse differed significantly between the 2 groups of patients according to WT1
expression post-SCT (P5.00003). Relapse in the 9 patients occurred at a median of 314 days (range, 50-560
days). Interestingly, in these patients, relapse was first predicted by WT1 (with negative FC and complete
chimerism) in 7 patients. WT1 overexpression was correlated with disease burden in patients with AML be-
fore and after allogeneic SCT. In patients who relapsed, both medullary and extramedullary relapse were bet-
ter anticipated by WT1 overexpression compared with FC and chimerism.
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Relapse and progression remain the main causes of
treatment failure in patients with acute myelogenous
leukemia (AML) after undergoing allogeneic
hemopoietic stem cell transplantation (SCT) and often
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6/j.bbmt.2012.01.012follow-up of minimal residual disease (MRD) after al-
logeneic SCT is of key importance for the early detec-
tion of relapse and the subsequent selection of patients
who may benefit frommodulation of immunosuppres-
sion or donor lymphocyte infusion (DLI). Various
methods with different sensitivities, including flow cy-
tometry (FC), chimerism, cytogenetics, and molecular
analysis, have been used in this setting [1]. FC has
become the gold standard for evaluating MRD in pa-
tients with acute lymphoblastic leukemia. However,
up to 20% of patients with AML lack appropriate
markers for MRD follow-up at diagnosis, and changes
in the original immunophenotype might occur in
relapse after SCT. Moreover, approximately 65% of
patients with AML lack a specific fusion transcript
that can serve as a molecular target for residual disease
monitoring. Chimerism analysis by RT-PCR, al-
though universally applicable in the postallogeneic1235
Table 1. Characteristics of 21 Patients with AML
Case Age, Years Sex FAB Karyotype FLT3/NPM1 Pre-SCT Status TPH Conditioning
Follow-Up,
Months
1 44 F M1 +4, +8 NA Relapse Bu/Flu 40
2 30 F M5b Normal NA CR1 Bu/CY 60
3 41 M M4 +8 NA CR1 Bu/CY 98
4 30 M M1 Normal Positive/negative CR, MRD+ TBI/CY 5
5 39 M RAEB-II Normal Negative/negative CR1, MRD+ 16
6 61 F M5 Complex Relapse 7.5
7 19 M M1 NA Negative/negative CR1 HLA-identical sibling 15
8 41 M M2 NA Positive/positive CR1 32
9 36 F M0 NA Positive/negative CR1 11
10 31 M M1 MLL+ Negative/negative CR1 Bu/Flu 23
11 44 M M1 Normal Negative/negative CR1 27
12 42 F TD Normal Negative/negative CR1, MRD+ 21
13 51 F M6 Normal Negative/negative CR1 21
14 35 F M4 Normal NA CR1 72
15 51 F M4 Normal Positive/positive CR1 MUD 19
16 39 F M1 Normal Negative/NA Relapse 5.6
17 44 M M2 Complex CR, MRD+ Bu/CY 14
18 24 F M4 Complex Relapse 47.5
19 45 M M1 Normal Positive/negative CR1 UCB/second-degree donor (dual) Bu/Flu/CY/ATG 26
20 34 F M4 Normal Negative/positive CR1 19
21 48 F M2 Iso(17q) NA CR1 Haploidentical Bu/Flu (RIC) 16
ATG indicates antithymocyte globulin; Bu, busulfan; CY, cyclophosphamide; Flu, fludarabine; NA, not available; UCB, unrelated cord blood; RIC, reduced-
intensity conditioning; TBI, total body irradiation.
1236 Biol Blood Marrow Transplant 18:1235-1242, 2012M. Kwon et al.SCT setting, has a sensitivity of only 0.1% to 1%. In
this context, new markers are needed to further con-
tribute to the spectrum of follow-up markers in the
posttransplantation period.
The Wilms’ tumor 1 gene (WT1), located on
chromosome 11p13, encodes a transcription factor
with both oncogene and tumor suppressor functions
[2]. WT1 is reportedly overexpressed in .90% of pa-
tients with AML and thus can be used for MRD mon-
itoring by quantitative RT-PCR [2-7]. Normal
hemopoietic cells have low WT1 expression, which
can be readily distinguished from expression in AML
cells by RT-PCR methods [5-7]. Several studies have
analyzed the role of WTI as a marker for MRD in
AML after chemotherapy and also as a predictor of
relapse after induction and/or consolidation therapy
[2,5,7-9]. A limited number of studies have focused
on MRD monitoring by WT1 transcript expression
in adults with AML after SCT [10-14]. The aim of
this study was to evaluate the usefulness of WT1
expression as a marker predictive of relapse in
patients with AML after SCT and to correlate the
results with those from FC and chimerism studies.PATIENTS AND METHODS
Patients
This study included 21 patients (12 females and 9
males) with AML who underwent allogeneic SCT in
our bone marrow transplantation unit between 2003
and 2010 and had ARN samples available for WT1
analysis. Demographic and clinical data at the time
of diagnosis and at transplantation are presented inTable 1. All patients hadWT1 overexpression at diag-
nosis or during follow-up before transplantation.
The median patient age at transplantation was 41
years (range, 19-61 years). All patients had poor-risk
AML with one or more of the following adverse fea-
tures: AML secondary to myelodysplastic syndrome,
high-risk cytogenetics, presence of FLT3-ITD, partial
remission (PR), more than one cycle to achieve com-
plete remission (CR), or disease status beyond first
CR. Only 3 patients had a specific molecular marker
forMRDmonitoring (NPM1mutation). Seventeen pa-
tients (80%) underwent myeloablative SCT (13 from
a sibling donor and 4 from amatched unrelated donor),
3 underwent dual transplantation (a single cord blood
unit with coinfusion of selected CD341 cells from
a non–HLA-identical related donor), and 1 patient un-
derwent a reduced-intensity conditioning SCT with
a haploidentical related donor (Table 1). Response to
therapy before and after transplantation was assessed
based on National Cancer Institute criteria, as revised
by the International Working Group in AML [15].
Samples
WT1 expression was assessed retrospectively in
a total of 300 samples, including 184 peripheral blood
(PB) samples and 116 bone marrow (BM) samples,
from the 21 patients (median, 15 samples per patient).
BM samples for chimerism and MRD analysis were
obtained before SCT and on days 130, 1100, 1180,
and 1365 post-SCT, and then once a year thereafter.
PB samples were obtained for chimerism determina-
tion starting on day 114 post-SCT. Patients with
mixed chimerism (MC) were studied in PB every other
week until complete chimerism (CC). Once CC was
Biol Blood Marrow Transplant 18:1235-1242, 2012 1237WT1 for MRD Monitoring after SCTachieved, studies were performed monthly during the
first year post-SCT, and every other month thereafter.
In addition, 12 BM samples and 11 PB samples
from healthy volunteer donors were tested as negative
controls, to define cutoff values of overexpression. All
samples were obtained after the patients and the do-
nors provided signed informed consent.
Quantitative Assessment of WT1 Transcript
Expression
Quantitative assessment of the WT1 transcript
amount was performed by quantitative RT-PCR. To-
tal RNA was purified from PB and BM samples using
TRIzol (Life Technologies, Carlsbad, CA), following
the manufacturer’s instructions. cDNA (30 mL) was
synthesized by reverse-transcription from 1 mg of total
RNA using Applied Biosystems High-Capacity RNA-
to-c-DNA Master Mix (Life Technologies) following
the manufacturer’s instructions and stored at 220C
until use. RT-PCR was performed in a Light Cycler
1.5 (Roche Applied Science, Mannheim, Germany)
using GUS as a reference gene and the K562 cell line
as a calibrator. The RT-PCR primers and Taqman
probes (TIB Molbiol, Berlin, Germany) for WT1
transcripts [16] were as follows: forward, 50-ACAG
GGTACGAGAGCGATAACCA-30 (exon 6, nt posi-
tion: 1205-1227, N,M_024426); reverse, 50-CACACG
TCGCACATCCTGAAT-30 (exon 6/7, nt position:
1289-1309, NM_024426), probe 50-6FAM-CAACGC
CCATCCTCTGCGGAGCCCA-TAMRA-30 (exon 6,
nt position: 1230-1254, NM_024426). The RT-PCR
primers and Taqman probes for GUS [17] were as fol-
lows: forward, 50-GAAAATATGTGGTTGGAGAGC
TCATT- 30 (nt position: 1759-1785; GenBank acces-
sion no. M15182); reverse, 50-CCGAGTGAAG
ATCCCCTTTTTA-30 (nt position: 1833-1859; Gene-
Bank accession no. M15182), and probe 50-6FAM-
CCAGCACTCTCGTCGGTGACTGTTCA-TAM
RA-30 (nt position: 1859-1881; GenBank accession no.
M15182). The PCR reactions were carried out in a
total volume of 10 mL containing 1  TaqMan Master
Mix (Roche Diagnostics), 0.5 mmol/L of each primer,
0.2 mmol/L of probe, and 3 mL of cDNA. The reaction
conditions were 10 minutes at 95C and 45 cycles of
94C for 10 seconds, then 60C for 30 seconds. In all
experiments, the K562 cell line was used as a positive
control, and sterilized water was used as a nontemplate
control.
All experiments were performed in duplicate, and
the mean value was recorded for further calculations.
If the results showed a discrepancy of .1 Ct between
duplicates, then the assay was repeated. Results were
analyzed with LightCycler SW 3.5 software package
(Roche Diagnostics). WT1 gene expression was calcu-
lated by relative quantification [18]using the normalized
ratio of the target gene (WT1) in relation to a reference
gene (GUS) and taking cell line K562 as the control(calibrator) sample. Results for each sample were
expressed as the percentage of the control, which was
arbitrarily assumed to have 100%WT1 expression.
FC Analysis of MRD
Leukemic aberrant phenotypes at diagnosis were
identified by 4-color combinations of monoclonal
antibodies and used for subsequent MRD detection
by multiparametric FC with a Cytomics FC-500 flow
cytometer (Beckman-Coulter, Brea, CA) with the
following combinations of monoclonal antibodies
(mAbs): FITC, PE, PE-Texas Red, and PE-Cy5:
CD13/CD33/CD45/CD34, CD38/CD56/CD45/
CD34, CD15/CD14/CD45/CD34, CD15/CD13/
CD34/CD33, CD64/CD11B/CD45/CD34, HLA-
DR/CD117/CD34/CD33, CD5/CD117/CD34/CD33,
CD7/CD34/CD45/CD2, CD20/CD19/CD34/CD45,
CD41/CD235a/CD45/CD34, and CD45/CD4/CD8/
CD3. All mAbs were purchased from Beckman-
Coulter. To enhance the sensitivity of the analysis,
data acquisition in the flow cytometer was performed
in 2 consecutive steps with a live gate, and information
was collected for at least 106 bone marrow-nucleated
cells. The CXP acquisition program (Beckman Coul-
ter) was used for acquisition. INFINICYT software
(Cytognos SL, Salamanca, Spain) was used for further
data analysis [19]. A percentage of leukemic cells ex-
ceeding 0.1% was considered a positive result.
Chimerism Analysis
Chimerism analysis was performed by short tan-
dem repeat PCR (STR-PCR). Total genomic DNA
was purified from BM and PB samples using the Max-
well 16 Blood DNA Purification Kit (Promega,
Madison, WI) following the manufacturer’s instruc-
tion. Multiplex STR-PCR was performed with 2 ng
of genomic DNA using the AmpFlSTR SGM Plus
Kit (Life Technologies), which contains 10 STR loci
plus the X-Y homolgous amelogenin gene labeled on
3 different colors (blue, 5-FAM; green, JOE; yellow,
NED). Amplified PCR products were subjected to
fragment analysis by capillary electrophoresis in an
ABI Prism 3100 automated DNA sequencer (Life
Technologies) under conditions recommended by
the manufacturer. Chimerism was quantified with
Genemapper 4.0 (Life Technologies), using the area
in pixels under diagnostic allele peaks to estimate the
amounts of donor and recipient DNA [20].
Statistical Analysis
Cutoff values of overexpression were defined as
median 1 2 SD of the WT1 expression values found
in control PB and BM samples from healthy donors.
Clinically relevant positive levels were considered after
2 consecutive measurements above the cutoff value.
Fisher’s exact test was used to evaluate the association
between WT1 overexpression and post-SCT relapse.
Figure 1. Results of WT1 expression in normal PB and BM samples to
calculate the cutoff level (mean1 2 SD) for positivity in patient samples
(PB, 0.025%; BM, 0.55%).
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WT1 Transcript Expression in Normal PB and
BM Samples
To determine the cutoff value for pathological
overexpression of WT1 in our laboratory, WT1 tran-
script expression was examined in 12 BM samples and
11 PB samples from healthy volunteer controls. Vary-
ing levels of WT1 expression were detected in the PB
(mean, 0.007%; range, 0.001%-0.019%) and BM
(mean, 0.26%; range, 0.004%-0.42%) samples. Ac-
cording to the mean 1 2 SD cutoff, values .0.025%
in PB and .0.55% in BM were considered positive
results (Figure 1).
WT1 Expression Pre-SCT
WT1 expression was correlated with the presence
of disease before SCT (Table 2). In fact, 8 patients
exhibited disease at the time of transplantation (4 re-
lapsed and 4 MRD-positive by FC). All 7 of these pa-
tients studied were positive for WT1. The remaining
13 patients underwent SCT while in CR with negative
MRD by FC, and none of 10 patients studied showed
WT1 overexpression. Of note, 3 of the 4 patients in
CR with positive MRD by FC and WT1 experienced
relapse after SCT.
WT1 Expression Post-SCT
Chimerism determination was available in all of
the 116 post-SCT BM samples, and MRD assessment
by FC was available in 77 of these samples. After SCT,
patients were classified according to WT1 dynamicsTable 2. Correlation of the Results Obtained from the Follow-Up o
Case Pre-SCT Status
WT1
Pre-SCT
Day of
Positive WT1
Post-SCTa
Day
Posit
to R
1 Relapse NA No
2 CR NA No
3 CR Negative No
4 CR, MRD+ Positive Continuous (PB, BM) 1
5 CRI, MRD+ Positive +118 (PB) 1
6 Relapse Positive +50 (PB)
7 CR1 NA +147 (BM)
8 CR1 Negative No
9 CR1 NA +260 (PB)
10 CR1 Negative +192 (PB) 2
11 CR1 Negative No
12 CRI, MRD+ Positive No
13 CR1 Negative No
14 CR1 Negative No
15 CR1 Negative No
16 Relapse Positive +43
17 CR, MRD+ Positive +285 (BM)
18 Relapse Positive Continuous 1
19 CR1 Negative No
20 CR1 Negative No
21 CR1 Negative +100 4
NA indicates not available.
To show the ability to anticipate relapse from WT1 expression follow-up, day
aPositive WT1 was defined as 2 consecutive evaluations with values above the(Figure 2). Eleven of the 21 patients showed negative
and stable WT1 levels in PB and BM on follow-up as-
sessment (Figure 2A and B). All of these 11 patients
showed CC and negative MRD by FC (Table 2) and
remained in CR with a median follow-up of 27 months
(range, 18-98 months). In 3 patients, NPM1 mutation
was available for molecular MRDmonitoring and also
remained negative throughout the follow-up. In this
group of patients, significant (up to 1 log) increasesf MRD by WT1 Expression, Chimerism, and FC
s from
ive WTl
elapse
Day of
Appearance
of MC
Day of
Positive FC
Evolution/Status
at Last Follow-Up
- - - CR, alive
- - - CR, alive
- - - CR, alive
40 +104 +153 Relapse day +153, exitus
49 Continuous +267 Relapse day +267, exitus
0 +50 - Relapse day +50, exitus
- - - CR, alive
- - - CR, alive
54 +314 +314 Relapse day +314, alive
83 - +475 Relapse day +475, alive
- - - CR, alive
- - - CR, alive
- - - CR, alive
- - - CR, alive
- - - CR, alive
57 +100 NA Relapse day +100, exitus
52 +337 +285 Relapse day +337, exitus
34 +314 NA Relapse day +314, alive
- - - CR, alive
- - - CR, alive
60 +292 NA Relapse day +560, exitus
s from positive WT1 expression and hematologic relapse are shown.
cutoff level for either PB or BM.
Figure 2. Evolution of WT1 expression in PB (upper panels, triangles) and BM (lower panels, circles) in patients with low and stable WT1 levels (left
panels) and patients with WT1 overexpression (right panels) after SCT. R, relapse post-SCT.
Biol Blood Marrow Transplant 18:1235-1242, 2012 1239WT1 for MRD Monitoring after SCTin WT1 expression were observed below the cutoff
value, followed by a further decrease in or stabilization
of theWT1 expression level. Only 1 patient (patient 8)
showed a significant increase in BM above the cutoff
value with a further decrease below the positivity level
while remaining in CR (Table 2 and Figure 2).
In contrast, 10 of the 21 patients exhibited WT1
overexpression after SCT (Table 2 and Figure 2C
and D). Nine of these 10 patients relapsed (all except
patient 7) (Figures 3 and S1). Among the 9 patients
who relapsed, 6 had initial negative values followed
by a significant increase in WT1 expression, reaching
positive levels in a median of 155 days (range, 50-285
days) after SCT and had positive values thereafter
(Figures 3 and S1). In contrast, 3 of the patients who
relapsed exhibited positive high values continuously
throughout the follow-up. Among the 9 relapsed pa-
tients, 2 had positive levels only in PB samples, 1 had
a positive level only in a BM sample, and 6 had positive
levels in both BM and PB samples (Figure 3). Three
patients with extramedullary relapse hadWT1 overex-
pression in PB only in 2 cases and in both PB and BM
in 1 case.
Relapse in the 9 patients occurred within a median
of 314 days (range, 50-560 days) after SCT. In one
case,WT1 overexpression together withMC occurred
at the time of hematologic relapse, whereas in the
other 8 patients, WT1 turned positive preceding re-
lapse at a median of 137 days (range, 52-462 days)
(Table 2). Interestingly, in 7 of these 8 relapsed pa-
tients, relapse was first predicted by positive WT1
(with negative FC and CC), whereas the remaining pa-
tient had MC together with positive WT1 (FC data
not available) (Figure 3).The incidence of relapse differed significantly (P5
.00003) between the 2 groups of patients according to
WT1 expression post-SCT. None of the 11 patients
without WT1 overexpression after SCT relapsed,
whereas 9 of 10 patients with WT1 overexpression
relapsed (Table 2 and Figure 2).
For 73 data points, both PB and BMwere available.
Results obtained in both sources were highly corre-
lated (Figure S2). In fact, 19 data points/samples
were positive, and 40 were negative in both PB and
BM, whereas only 14 samples had discordant results.
Nine samples from 6 patients were negative in PB
but positive in BM. Five of these 6 patients did not re-
lapse and had positive WT1 results in BM early after
SCT, with negative values thereafter in PB and BM.
One patient had positive WT1 in BM but negative
WT1 in PB after hematologic relapse. On the other
hand, 5 samples from 5 different patients showed pos-
itive WT1 results in PB but negative results in BM.
Four of these patients relapsed. In 1 patient, the posi-
tive result in PB was detected immediately after SCT,
whereas in the other 3 patients, PB turned positive
while remained BM negative; these patients experi-
enced extramedullary relapse.DISCUSSION
Detection and monitoring of MRD in patients
with AML after SCT together with chimerism analysis
are important to assess remission and early relapse
management [1,10-14]. Unfortunately, only 40% of
AML cases show a specific molecular marker for
MRD evaluation. Because more than 90% of patients
with AML show WT1 overexpression, WT1 has
Figure 3. Comparison of the results obtained fromWT1 expression, chimerism (C), and FC for the follow up of MRD in PB (triangles) and BM (circles)
from patients who relapsed after SCT. Positive results are identified by solid black symbols (triangles or circles), and negative results appear as hollow
white symbols. Contiguous symbols (triangles and circles) represent PB and BM samples obtained on the same day. Vertical gray bars indicate the time of
hematologic relapse. Patient numbers are identical to those in Tables 1 and 2 and Figure S1.
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monitoring, including evaluation of MRD after
chemotherapy or SCT, as long as a quantitative RT-
PCR method is used [10-14].
The variable expression of WT1 in normal PB
and BM must be addressed before WT1 can be used
as an MRD marker [1-7,8,10]. In our laboratory,
we determined the cutoff value for pathological
overexpression of WT1 by evaluating BM and PB
samples from healthy volunteer donors. Positive
values were defined as the median 1 2 SD of WT1
expression in normal samples.
We found a good correlation between WT1 gene
expression and disease status before and after alloge-
neic SCT. Before transplantation, WT1 was positive
in all patients with disease in a visible phase or with
positive MRD by FC (7 of 7) and was negative in the
patients with negative MRD as measured by FC (0 of
10) (Table 2). During the posttransplantation period,
high concordance between normal WT1 expression
level and remission status was seen in patients in CR.
In all patients, WT1 levels remained below cutoff
levels throughout the follow-up period and were con-
sistent with morphological and immunophenotypic
BM analysis, PB and BM chimerism testing, and detec-
tion of molecular-specific markers (when available).
Conversely, the majority of patients (9 of 10) with
posttransplantation WT1 overexpression experienceddisease recurrence (Figures 3 and S1). None of
these patients had a low WT1 level at the time of
hematologic relapse, confirming that WT1 over-
expression is a marker of AML activity. WT1 positivity
occurred significantly earlier than hematologic
relapse in 8 of 9 patients and also earlier than
conversion from full donor to MC or FC positivity in
7 of these 8 patients, demonstrating the predictive
capacity of WT1 for hematologic relapse (Figure 3).
In concordance with previous studies [12,13],
variability in the kinetics of WT1 increase was seen
in the patients who relapsed after allogeneic SCT;
some of the patients displayed a low and steady rise
of WT1 transcripts, whereas others had a rapid
growth in gene expression level. However, the
molecular diagnosis and morphological diagnosis of
AML relapse were concomitant in only 1 patient
(Figure 2). Therefore, patients in CR after SCT but
with a progressive and slow increase in WT1 levels
and without signs of graft-versus-host disease might
be candidates for modulation of immune suppression
either by suspension of drug therapy or, in selected
cases, by preemptive DLI [11-14] to avoid disease
relapse.
Good correlation of WT1 expression in PB and
BM was observed (Figure S2). Six patients had a nega-
tive PB sample with a positive BM sample; however,
this occurred early after SCT, with negative PB and
Biol Blood Marrow Transplant 18:1235-1242, 2012 1241WT1 for MRD Monitoring after SCTBM seen thereafter, and thus this observation has no
clinical implications. Conversely, 5 patients had
a positive PB sample with a negative BM sample.
Four of these patients relapsed, 3 with extramedullary
relapse. Interestingly, the patients with extramedullary
disease, although not anticipated byWT1 level in BM,
had WT1 overexpression in PB samples, which could
allow appropriate anticipation of disease relapse
(Figures 3 and S1). We hypothesize that the
increased capability to detect AML cells in the PB in
this context could be due to the higher sensitivity of
the assay in PB compared with BM, as well as the
probable detection of circulating leukemic cells
derived from extramedullary sites. Considering the
high correlation between the results in PB and BM,
the higher sensitivity of the assay in PB, and the
greater ability to detect extramedullary relapses, it
can be argued that PB analysis is suitable for the
follow-up of WT1 expression in patients with AML
after SCT.
Our results show that absoluteWT1 values are less
clinically informative than WT1 expression dynamics
in patient follow-up. In this scenario, the relative quan-
tification approach used here is fully applicable for the
follow-up of MRD in patients with AML on a routine
clinical basis. Moreover, any control sample (K562 in
our case) could be used to normalize WT1 expression
values, provided that it is available for this purpose. Fi-
nally, being equally useful, this approach is faster,
cheaper, and easier compared with techniques based
on absolute quantifications.
In conclusion, our findings indicate that WT1
overexpression was correlated with disease burden in
patients with AML before and after allogeneic SCT.
In relapsed patients, both medullar and extramedullar
relapse were significantly anticipated by WT1 overex-
pression compared with FC and chimerism. Because
immunotherapy is clearly more effective for patients
with a low tumor burden (ie, at molecular relapse)
[21], monitoring of MRD by quantitative assessment
of WT1 level may have a favorable impact on the
prognosis of relapsed patients after allogeneic SCT.
Therefore, quantification of WT1 overexpression by
quantitative RT-PCR should be used for MRD detec-
tion during the post-SCT follow-up after SCT in
patients with AML to facilitate immunosuppressive
therapy and identify candidates for early DLI.ACKNOWLEDGMENT
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